MX2021000611A - Una sal de xinafoato de un compuesto inhibidor de jak. - Google Patents

Una sal de xinafoato de un compuesto inhibidor de jak.

Info

Publication number
MX2021000611A
MX2021000611A MX2021000611A MX2021000611A MX2021000611A MX 2021000611 A MX2021000611 A MX 2021000611A MX 2021000611 A MX2021000611 A MX 2021000611A MX 2021000611 A MX2021000611 A MX 2021000611A MX 2021000611 A MX2021000611 A MX 2021000611A
Authority
MX
Mexico
Prior art keywords
inhibiting compound
xinafoate salt
jak
jak inhibiting
xinafoate
Prior art date
Application number
MX2021000611A
Other languages
English (en)
Inventor
James Mccabe
Anna Matilda Angelica Pettersen
Carl - Johan AURELL
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2021000611A publication Critical patent/MX2021000611A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente divulgación se refiere a sales de compuestos de Fórmula (I) preparadas como una sal de xinafoato (1-hidroxi-2-naftoato) (Fórmula (Ia)), composiciones farmacéuticamente aceptables que las comprenden y métodos para utilizarlas. Fórmula (Ia).
MX2021000611A 2018-07-18 2019-07-17 Una sal de xinafoato de un compuesto inhibidor de jak. MX2021000611A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862699955P 2018-07-18 2018-07-18
US201962866013P 2019-06-25 2019-06-25
PCT/EP2019/069252 WO2020016302A1 (en) 2018-07-18 2019-07-17 A xinafoate salt of a jak inhibiting compound

Publications (1)

Publication Number Publication Date
MX2021000611A true MX2021000611A (es) 2021-04-13

Family

ID=67396927

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000611A MX2021000611A (es) 2018-07-18 2019-07-17 Una sal de xinafoato de un compuesto inhibidor de jak.

Country Status (13)

Country Link
US (1) US11149029B2 (es)
EP (1) EP3823964A1 (es)
JP (2) JP7422732B2 (es)
KR (1) KR20210033474A (es)
CN (1) CN112424187B (es)
AU (1) AU2019304014B2 (es)
BR (1) BR112021000467A2 (es)
CA (1) CA3105585A1 (es)
IL (1) IL280025A (es)
MA (1) MA53162A (es)
MX (1) MX2021000611A (es)
SG (1) SG11202100240RA (es)
WO (1) WO2020016302A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193181B2 (en) * 2007-09-05 2012-06-05 Rigel Pharmaceuticals, Inc. Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine
CN103209695A (zh) * 2010-09-15 2013-07-17 弗·哈夫曼-拉罗切有限公司 氮杂苯并噻唑化合物、组合物及应用方法
PE20161073A1 (es) * 2013-11-01 2016-10-30 Novartis Ag Amino-heteroaril-benzamidas como inhibidores de cinasa
SI3189045T1 (sl) * 2014-08-11 2022-05-31 Sun Pharmaceutical Industries Limited Nove soli nilotiniba in njih polimorfi
CN108368091B (zh) 2015-09-25 2020-08-11 迪哲（江苏）医药有限公司 用于抑制jak的化合物和方法
RS63981B1 (sr) * 2017-01-17 2023-03-31 Astrazeneca Ab Selektivni inhibitori jak1
CN106831538B (zh) * 2017-01-22 2019-06-25 苏州楚凯药业有限公司 托法替尼中间体的制备方法

Also Published As

Publication number Publication date
BR112021000467A2 (pt) 2021-04-06
JP2024001109A (ja) 2024-01-09
US11149029B2 (en) 2021-10-19
MA53162A (fr) 2021-05-26
CN112424187A (zh) 2021-02-26
WO2020016302A1 (en) 2020-01-23
SG11202100240RA (en) 2021-02-25
JP7422732B2 (ja) 2024-01-26
AU2019304014A1 (en) 2021-03-04
WO2020016302A8 (en) 2020-11-12
EP3823964A1 (en) 2021-05-26
IL280025A (en) 2021-03-01
KR20210033474A (ko) 2021-03-26
JP2021530526A (ja) 2021-11-11
US20200062737A1 (en) 2020-02-27
CA3105585A1 (en) 2020-01-23
AU2019304014B2 (en) 2022-08-18
CN112424187B (zh) 2024-06-21

Similar Documents

Publication Publication Date Title
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12018501099A1 (en) Novel biphenyl compound or salt thereof
MX2021003460A (es) Fabricacion de compuestos y composiciones para inhibir la actividad de shp2.
CA2875877C (en) Syk inhibitors
MX2017010735A (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
PH12017500281B1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12017501429A1 (en) Derivatives of betulin
EA033168B1 (ru) СТИМУЛЯТОРЫ sGC
PH12016500169A1 (en) Polymorph of syk inhibitors
PH12018501644A1 (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
MY197698A (en) Oxysterols and methods of use thereof
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
MY185971A (en) Pyranodipyridine compound
MX2018001925A (es) Composiciones que comprenden compuestos triciclicos heterociclicos.
MX2023009037A (es) Compuesto de pirimidopirano.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
MX2021001904A (es) Formas solidas de benzoxaborol sustituido y composiciones de las mismas.
MX2016007985A (es) Compuestos de fluorofenilpirazol.
MX2021000611A (es) Una sal de xinafoato de un compuesto inhibidor de jak.
MX2019011558A (es) Nuevos compuestos sustituidos de n'-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido).
PH12021550248A1 (en) Borate of azetidine derivative